8-K: Eli Lilly Reports Strong Q2 2026, Boosts Full-Year Guidance

Eli Lilly and Company announced robust second-quarter 2026 financial results, driven by Mounjaro and Zepbound, and raised its full-year revenue and non-GAAP EPS guidance.

Summary

• Eli Lilly and Company reported a 48% increase in second-quarter 2026 revenue, reaching $23.0 billion, primarily driven by Mounjaro and Zepbound sales.
• Reported Earnings Per Share (EPS) rose 26% to $7.94, while non-GAAP EPS increased 33% to $8.38.
• Full-year 2026 revenue guidance was raised to a range of $85.0 billion to $87.0 billion.
• Non-GAAP EPS guidance for the full year was also increased, with an updated range of $35.50 to $36.50.
• The company secured regulatory approvals for Ebglyss and Jaypirca, and submitted orforglipron for type 2 diabetes.
• Pipeline advancements include positive Phase 3 data for retatrutide in obesity, with global registration submissions planned for Q1 2027.
• Significant business development activity occurred with the acquisition of multiple companies, including Orna Therapeutics and Ajax Therapeutics.
• An additional $4.5 billion was committed to expand manufacturing sites in Indiana.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a strongly positive report, characterized by significant revenue growth, increased full-year guidance, and robust pipeline progress, indicating strong operational performance and future potential.

Positives

• Revenue surged 48% to $23.0 billion in Q2 2026, significantly exceeding prior year performance.
• Mounjaro and Zepbound were primary drivers of revenue growth, with Mounjaro revenue up 91% and Zepbound revenue up 46%.
• Full-year revenue guidance was increased to $85.0 billion $87.0 billion.
• Full-year non-GAAP EPS guidance was raised, with the midpoint increasing by $2.78.
• Gross margin increased 50% to $19.7 billion, with gross margin as a percent of revenue improving to 85.8%.
• Positive Phase 3 trial results for retatrutide in obesity, obstructive sleep apnea, and knee osteoarthritis pain.
• FDA approval for Ebglyss for a new maintenance dose and European Commission approval for Jaypirca.
• Strategic acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics to bolster the pipeline.

Negatives

• Reported and non-GAAP EPS included $3.03 of acquired IPR&D charges in Q2 2026, compared to $0.14 in Q2 2025, impacting reported earnings.
• Realized prices decreased by 13% overall, driven by lower prices for Zepbound and Mounjaro in the U.S. and the addition of Mounjaro to the NRDL in China.
• Acquired IPR&D charges of $2.8 billion in Q2 2026 significantly impacted net income and EPS.
• Asset impairment, restructuring and other special charges of $703 million in Q2 2026, primarily related to acquisition and integration costs.
• The effective tax rate increased to 23.3% in Q2 2026 from 16.5% in Q2 2025, largely due to non-deductible acquired IPR&D charges.

Risks

• The significant costs and uncertainties in the pharmaceutical research and development process, including regulatory approval timelines.
• The impact and uncertain outcome of acquisitions and business development transactions, including related costs.
• Intense competition affecting the company's products, pipeline, or industry.
• Continued pricing pressures and the impact of governmental and private actors affecting pricing, reimbursement, and patient access.
• Issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages.
• The expiration of intellectual property protection for certain products and competition from generic and biosimilar products.
• Risks associated with the use of artificial intelligence or other emerging technologies in operations.
• Global macroeconomic conditions, including uneven economic growth, trade disputes, and international tensions.

Future Outlook

Full-year 2026 revenue guidance has been raised to $85.0 billion to $87.0 billion. Non-GAAP EPS guidance for the full year has been updated to $35.50 to $36.50, reflecting strong underlying business growth offset by acquired IPR&D charges. The company plans to submit a Biologics License Application to the U.S. FDA for retatrutide in Q1 2027.

Management Comments

• "Lilly's momentum continues, as we delivered 48% revenue growth and raised our full-year guidance," said David A. Ricks, Lilly chair and CEO.
• "At the same time, Lilly is building for the future. With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development, Lilly's future, after 150 years, has never been brighter."

Industry Context

StockSavvy.ai notes that Eli Lilly's strong performance, particularly with Mounjaro and Zepbound, aligns with the significant market demand for effective obesity and diabetes treatments. The company's aggressive business development and pipeline advancements, including retatrutide, position it to maintain leadership in these high-growth therapeutic areas, while also facing increasing competition and regulatory scrutiny on pricing.

Comparison to Industry Standards

• Eli Lilly's Q2 2026 revenue growth of 48% significantly outpaces the average revenue growth for large pharmaceutical companies, which typically ranges from low to mid-single digits.
• The reported EPS growth of 26% and non-GAAP EPS growth of 33% are exceptionally strong, especially considering the substantial acquired IPR&D charges.
• The company's commitment of an additional $4.5 billion to manufacturing expansion is a substantial investment, reflecting confidence in future demand and a strategic move to secure supply chains, a critical factor in the pharmaceutical industry.
• The successful acquisition of multiple biotech companies (Orna, Ajax, Centessa, Kelonia) demonstrates a proactive strategy for pipeline enhancement, a common but often challenging practice in the industry. Competitors like Pfizer and Merck also engage in similar M&A activities to bolster their portfolios.

Legal Proceedings

• Asset impairment, restructuring and other special charges for the six months ended June 30, 2026, included charges related to litigation matters.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue, raised guidance, and strong pipeline progress, likely leading to potential stock price appreciation.
• Employees: Potential for increased job security and opportunities due to company growth and expansion, but also potential impact from acquisition integration.
• Customers (Patients): Continued access to innovative treatments for diabetes, obesity, and other conditions, with potential for new therapies from pipeline advancements.
• Suppliers: Increased demand for raw materials and services due to expanded manufacturing and higher production volumes.
• Creditors: Improved financial health and profitability may enhance the company's creditworthiness.

Next Steps

• Submit a Biologics License Application to the U.S. FDA for retatrutide in Q1 2027.
• Continue to build out infectious disease portfolio through acquisitions.
• Expand Indiana manufacturing sites with an additional $4.5 billion investment.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with significant revenue growth and raised full-year guidance, driven by blockbuster drugs and a robust pipeline. Strategic acquisitions and manufacturing expansions further solidify its market position and future growth prospects, making it a compelling investment.

Keywords

Mounjaro, Zepbound, retatrutide, obesity, diabetes, pharmaceuticals, revenue growth, pipeline